Breakthrough in China’s CAR-T Therapy for Treating Relapsed B-ALL: Donor-Derived CD19 CAR-T Shows Long-Term Survival Advantage

**Breakthrough in China’s CAR-T Therapy for Treating Relapsed B-ALL: Donor-Derived CD19 CAR-T Shows Long-Term Survival Advantage**

B-ALL

#CAR_TTherapy #B_ALL #DonorCAR_T #CAR_T #ALL #ChinaCART #CD19 #alloHSCT

In recent years, China has made significant strides in CAR-T cell therapy, particularly in treating B-cell acute lymphoblastic leukemia (B-ALL). Donor-derived CAR-T therapy has shown promising efficacy for B-ALL patients who relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT), bringing new hope for long-term survival.

A study jointly published by the Chinese Academy of Medical Sciences and Chinese medical teams in the *Journal of Hematology & Oncology*, titled “Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopoietic stem cell transplantation,” indicates that patients treated with donor CD19 CAR-T cells achieved complete remission (CR) without requiring a second transplant, with a significant increase in long-term survival rates. This study followed 32 B-ALL patients who relapsed post-allo-HSCT. The median patient age was 24, and after receiving donor CD19 CAR-T therapy, they achieved complete remission or partial recovery in peripheral blood (CRi), with a median follow-up of 42 months.

Results showed that patients treated with donor CD19 CAR-T had a 2-year overall survival (OS) rate of 56.25% and an event-free survival (EFS) rate of 50.0%. The 5-year OS and EFS reached 53.13% and 46.88%, respectively, with no new long-term adverse events. These findings suggest that donor CAR-T cells are not only effective but also have long-term safety advantages over second transplantation or traditional donor lymphocyte infusion, offering a more promising treatment option for relapsed B-ALL patients.

While these results are encouraging, further development of early detection methods is needed to identify or prevent relapse at an earlier stage. Early relapse with donor CAR-T, especially within the first six months post-treatment, remains a challenge, requiring additional multi-center, prospective studies for validation. Overall, this research provides robust clinical data supporting donor CAR-T therapy for relapsed B-ALL patients post-transplant, potentially establishing a benchmark for CAR-T therapies in China on a global scale.

🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#ChinaMedicalBreakthrough #CancerResearch #Hematology #Oncology #LongTermSurvival #StemCellTransplantation #RelapsedLeukemia #ChineseMedicalResearch